PARTNER WITH US
The oNKo-innate platforms encompass three discovery approaches that can be adapted to the research interests and specified goals of our partners. We also have multiple pipeline assets in pre-clinical development that are available for commercialization partnerships.
We’re open to synergistic, value-driving industry partnerships and academic collaborations across the following key areas:
Immuno-Oncology Target Discovery
- Harness the power of our advanced screening platform to identify targets in primary human immune cells and validate new hits with our in vitro and in vivo approaches.
- For immune cell phenotypic screening, utilize our CRISPR and immsigHTS platforms.
First-In-Class Validated Cytokine Checkpoint Targets
- Drive small-molecule drug discovery campaigns for targets like our oNKo-037 asset.
- License and optimize cytokine checkpoints as targets for edited cell therapies.
Tumor Microenvironment Targeting
- Tackle the complex tumor microenvironment by licensing our oNKo-001 asset: a novel reduced-potency IL-12v-Fc.
Partner with Us
Any target, any cell type. Join forces with oNKo-innate and help drive the immuno-oncology revolution!